hydralazine has been researched along with Inflammation in 21 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aims to investigate the effects of hydralazine on inflammation induced by spinal cord injury (SCI) in the central nervous system (CNS) and its mechanism in promoting the structural and functional recovery of the injured CNS." | 8.31 | Hydralazine Promotes Central Nervous System Recovery after Spinal Cord Injury by Suppressing Oxidative Stress and Inflammation through Macrophage Regulation. ( Guo, K; Ma, T; Qi, CC; Quan, X; Song, BQ; Wang, H; Yu, CY, 2023) |
| " Obesity increased albuminuria and glomerulosclerosis, which were significantly ameliorated by low-dose hydralazine in the absence of a blood pressure-lowering effect." | 8.12 | Low-dose hydralazine reduces albuminuria and glomerulosclerosis in a mouse model of obesity-related chronic kidney disease. ( Chen, H; Chen, J; Faiz, A; Glastras, SJ; Hou, M; Larkin, BP; Nguyen, LT; Pollock, CA; Saad, S; Wang, R, 2022) |
| "Gestational hydralazine reduced renal global DNA methylation in offspring of obese mothers and attenuated maternal obesity-induced renal fibrosis." | 8.02 | Low-dose hydralazine during gestation reduces renal fibrosis in rodent offspring exposed to maternal high fat diet. ( Chen, H; Glastras, SJ; Hou, M; Larkin, BP; Nguyen, LT; Pollock, CA; Saad, S; Wang, R, 2021) |
| " Here, we aimed to determine whether lowering blood pressure with hydralazine might prevent inflammation and cardiac fibrosis in response to angiotensin II." | 7.77 | Angiotensin II infusion-induced inflammation, monocytic fibroblast precursor infiltration, and cardiac fibrosis are pressure dependent. ( Bian, Y; Cheng, J; Du, J; Jia, L; Li, H; Li, Y; Qi, G; Xiao, C, 2011) |
| " Despite comparable hypotensive effects between valsartan and hydralazine in salt-loaded SHRSP, valsartan reduced cerebral NADPH oxidase activity and ROS more than hydralazine being accompanied by more prevention of stroke by valsartan than hydralazine." | 7.74 | Excess salt causes cerebral neuronal apoptosis and inflammation in stroke-prone hypertensive rats through angiotensin II-induced NADPH oxidase activation. ( Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tamamaki, N; Tokutomi, Y; Yamamoto, E, 2008) |
| "We investigated the effects of treatment with the angiotensin II type 1 receptor antagonist, telmisartan, on abdominal aortic aneurysm formation in normotensive rats." | 7.74 | Telmisartan prevents aneurysm progression in the rat by inhibiting proteolysis, apoptosis and inflammation. ( Grzesiak, A; Kaschina, E; Kemnitz, UR; Krikov, M; Schrader, F; Sommerfeld, M; Unger, T, 2008) |
| "Angiotensin II (Ang II) is a potent vasoconstrictor and induces inflammation and end-organ injury through its activation of the proinflammatory transcription factor, nuclear factor-kappaB (NF-kappaB)." | 7.72 | Heat shock treatment protects against angiotensin II-induced hypertension and inflammation in aorta. ( Chen, Y; Currie, RW; Ross, BM, 2004) |
| " We tested the hypothesis that endothelin (ET)(A/B) receptor blockade with bosentan (100 mg/kg by gavage after age 4 weeks) ameliorates cardiac and renal damage by decreasing inflammation in rats harboring both human renin and angiotensinogen genes (dTGR)." | 7.70 | Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. ( Breu, V; Dechend, R; Ganten, D; Genersch, E; Haller, H; Löffler, BM; Luft, FC; Mervaala, EM; Muller, DN; Park, JK; Schmidt, F; Schneider, W, 2000) |
| "Hydralazine has shown renoprotective effects in multiple kidney diseases and was shown to be a potent xanthine oxidase (XO) inhibitor." | 5.91 | Xanthine oxidase/NADPH oxidase inhibition by hydralazine attenuates acute kidney injury and prevents the transition of acute kidney injury to chronic kidney disease. ( Chang, TT; Chen, C; Chen, JW; Chiang, CH; Fang, SY; Lin, SC, 2023) |
| "Sepsis is an amplified systemic immune-inflammatory response produced by a microorganism, which involves activation of inflammatory cytokine signaling pathways and oxidative stress." | 5.62 | The Therapeutic Value of Hydralazine in Reducing Inflammatory Response, Oxidative Stress, and Mortality in Animal Sepsis: Involvement of the PI3K/AKT Pathway. ( Assreuy, J; Da Silva, EAP; Heimfarth, L; Júnior, LJQ; Marinho, YYM; Menezes, IAC; Oliveira, JYS; Pereira, EWM; Santana, IR; Santos, DMD; Santos, MRVD, 2021) |
| "This study aims to investigate the effects of hydralazine on inflammation induced by spinal cord injury (SCI) in the central nervous system (CNS) and its mechanism in promoting the structural and functional recovery of the injured CNS." | 4.31 | Hydralazine Promotes Central Nervous System Recovery after Spinal Cord Injury by Suppressing Oxidative Stress and Inflammation through Macrophage Regulation. ( Guo, K; Ma, T; Qi, CC; Quan, X; Song, BQ; Wang, H; Yu, CY, 2023) |
| " Obesity increased albuminuria and glomerulosclerosis, which were significantly ameliorated by low-dose hydralazine in the absence of a blood pressure-lowering effect." | 4.12 | Low-dose hydralazine reduces albuminuria and glomerulosclerosis in a mouse model of obesity-related chronic kidney disease. ( Chen, H; Chen, J; Faiz, A; Glastras, SJ; Hou, M; Larkin, BP; Nguyen, LT; Pollock, CA; Saad, S; Wang, R, 2022) |
| "Gestational hydralazine reduced renal global DNA methylation in offspring of obese mothers and attenuated maternal obesity-induced renal fibrosis." | 4.02 | Low-dose hydralazine during gestation reduces renal fibrosis in rodent offspring exposed to maternal high fat diet. ( Chen, H; Glastras, SJ; Hou, M; Larkin, BP; Nguyen, LT; Pollock, CA; Saad, S; Wang, R, 2021) |
| " Here, we aimed to determine whether lowering blood pressure with hydralazine might prevent inflammation and cardiac fibrosis in response to angiotensin II." | 3.77 | Angiotensin II infusion-induced inflammation, monocytic fibroblast precursor infiltration, and cardiac fibrosis are pressure dependent. ( Bian, Y; Cheng, J; Du, J; Jia, L; Li, H; Li, Y; Qi, G; Xiao, C, 2011) |
| " Another set of rats were treated with hydralazine (25 mg/kg per day orally) to determine the pressure-independent effects of HDAC inhibition on hypertension." | 3.76 | HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. ( Cardinale, JP; Elks, CM; Francis, J; Guggilam, A; Mariappan, N; Pariaut, R; Sriramula, S, 2010) |
| " Despite comparable hypotensive effects between valsartan and hydralazine in salt-loaded SHRSP, valsartan reduced cerebral NADPH oxidase activity and ROS more than hydralazine being accompanied by more prevention of stroke by valsartan than hydralazine." | 3.74 | Excess salt causes cerebral neuronal apoptosis and inflammation in stroke-prone hypertensive rats through angiotensin II-induced NADPH oxidase activation. ( Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tamamaki, N; Tokutomi, Y; Yamamoto, E, 2008) |
| "We investigated the effects of treatment with the angiotensin II type 1 receptor antagonist, telmisartan, on abdominal aortic aneurysm formation in normotensive rats." | 3.74 | Telmisartan prevents aneurysm progression in the rat by inhibiting proteolysis, apoptosis and inflammation. ( Grzesiak, A; Kaschina, E; Kemnitz, UR; Krikov, M; Schrader, F; Sommerfeld, M; Unger, T, 2008) |
| "Angiotensin II (Ang II) is a potent vasoconstrictor and induces inflammation and end-organ injury through its activation of the proinflammatory transcription factor, nuclear factor-kappaB (NF-kappaB)." | 3.72 | Heat shock treatment protects against angiotensin II-induced hypertension and inflammation in aorta. ( Chen, Y; Currie, RW; Ross, BM, 2004) |
| " We tested the hypothesis that endothelin (ET)(A/B) receptor blockade with bosentan (100 mg/kg by gavage after age 4 weeks) ameliorates cardiac and renal damage by decreasing inflammation in rats harboring both human renin and angiotensinogen genes (dTGR)." | 3.70 | Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. ( Breu, V; Dechend, R; Ganten, D; Genersch, E; Haller, H; Löffler, BM; Luft, FC; Mervaala, EM; Muller, DN; Park, JK; Schmidt, F; Schneider, W, 2000) |
| "Preeclampsia is characterized by blood pressure greater than 140/90 mmHg in the second half of pregnancy." | 2.55 | Pathophysiology and Current Clinical Management of Preeclampsia. ( Amaral, LM; LaMarca, B; Owens, M; Wallace, K, 2017) |
| "Hydralazine has shown renoprotective effects in multiple kidney diseases and was shown to be a potent xanthine oxidase (XO) inhibitor." | 1.91 | Xanthine oxidase/NADPH oxidase inhibition by hydralazine attenuates acute kidney injury and prevents the transition of acute kidney injury to chronic kidney disease. ( Chang, TT; Chen, C; Chen, JW; Chiang, CH; Fang, SY; Lin, SC, 2023) |
| "Sepsis is an amplified systemic immune-inflammatory response produced by a microorganism, which involves activation of inflammatory cytokine signaling pathways and oxidative stress." | 1.62 | The Therapeutic Value of Hydralazine in Reducing Inflammatory Response, Oxidative Stress, and Mortality in Animal Sepsis: Involvement of the PI3K/AKT Pathway. ( Assreuy, J; Da Silva, EAP; Heimfarth, L; Júnior, LJQ; Marinho, YYM; Menezes, IAC; Oliveira, JYS; Pereira, EWM; Santana, IR; Santos, DMD; Santos, MRVD, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (19.05) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 5 (23.81) | 24.3611 |
| 2020's | 5 (23.81) | 2.80 |
| Authors | Studies |
|---|---|
| Larkin, BP | 2 |
| Nguyen, LT | 2 |
| Hou, M | 2 |
| Glastras, SJ | 2 |
| Chen, H | 2 |
| Faiz, A | 1 |
| Chen, J | 1 |
| Wang, R | 2 |
| Pollock, CA | 2 |
| Saad, S | 2 |
| Chiang, CH | 1 |
| Chen, C | 1 |
| Fang, SY | 1 |
| Lin, SC | 1 |
| Chen, JW | 1 |
| Chang, TT | 1 |
| Quan, X | 1 |
| Ma, T | 1 |
| Guo, K | 1 |
| Wang, H | 1 |
| Yu, CY | 1 |
| Qi, CC | 1 |
| Song, BQ | 1 |
| Santos, DMD | 1 |
| Da Silva, EAP | 1 |
| Oliveira, JYS | 1 |
| Marinho, YYM | 1 |
| Santana, IR | 1 |
| Heimfarth, L | 1 |
| Pereira, EWM | 1 |
| Júnior, LJQ | 1 |
| Assreuy, J | 1 |
| Menezes, IAC | 1 |
| Santos, MRVD | 1 |
| Amaral, LM | 1 |
| Wallace, K | 1 |
| Owens, M | 1 |
| LaMarca, B | 1 |
| Due, MR | 1 |
| Park, J | 1 |
| Zheng, L | 1 |
| Walls, M | 1 |
| Allette, YM | 1 |
| White, FA | 1 |
| Shi, R | 1 |
| Yamamoto, E | 1 |
| Tamamaki, N | 1 |
| Nakamura, T | 1 |
| Kataoka, K | 1 |
| Tokutomi, Y | 1 |
| Dong, YF | 1 |
| Fukuda, M | 1 |
| Matsuba, S | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Kaschina, E | 1 |
| Schrader, F | 1 |
| Sommerfeld, M | 1 |
| Kemnitz, UR | 1 |
| Grzesiak, A | 1 |
| Krikov, M | 1 |
| Unger, T | 1 |
| Cardinale, JP | 1 |
| Sriramula, S | 1 |
| Pariaut, R | 1 |
| Guggilam, A | 1 |
| Mariappan, N | 1 |
| Elks, CM | 1 |
| Francis, J | 1 |
| Qi, G | 1 |
| Jia, L | 1 |
| Li, Y | 1 |
| Bian, Y | 1 |
| Cheng, J | 1 |
| Li, H | 1 |
| Xiao, C | 1 |
| Du, J | 1 |
| Villa, L | 1 |
| Boor, P | 1 |
| Konieczny, A | 1 |
| Kunter, U | 1 |
| van Roeyen, CR | 1 |
| Denecke, B | 1 |
| Gan, L | 1 |
| Neusser, MA | 1 |
| Cohen, CD | 1 |
| Eitner, F | 1 |
| Scholl, T | 1 |
| Ostendorf, T | 1 |
| Floege, J | 1 |
| Leiro, JM | 1 |
| Alvarez, E | 1 |
| Arranz, JA | 1 |
| Cano, E | 1 |
| Orallo, F | 1 |
| Chen, Y | 1 |
| Ross, BM | 1 |
| Currie, RW | 1 |
| Muller, DN | 1 |
| Mervaala, EM | 1 |
| Schmidt, F | 1 |
| Park, JK | 1 |
| Dechend, R | 1 |
| Genersch, E | 1 |
| Breu, V | 1 |
| Löffler, BM | 1 |
| Ganten, D | 1 |
| Schneider, W | 1 |
| Haller, H | 1 |
| Luft, FC | 1 |
| Kataoka, C | 1 |
| Egashira, K | 1 |
| Inoue, S | 1 |
| Takemoto, M | 1 |
| Ni, W | 1 |
| Koyanagi, M | 1 |
| Kitamoto, S | 1 |
| Usui, M | 1 |
| Kaibuchi, K | 1 |
| Shimokawa, H | 1 |
| Takeshita, A | 1 |
| Sasaki, K | 1 |
| Murohara, T | 1 |
| Ikeda, H | 1 |
| Sugaya, T | 1 |
| Shimada, T | 1 |
| Shintani, S | 1 |
| Imaizumi, T | 1 |
| Drózdz, M | 2 |
| Kucharz, E | 2 |
| Wieczorek, M | 2 |
| Floersheim, GL | 1 |
| Bucher, K | 1 |
| Paolini, JP | 1 |
| Lendvay, LJ | 1 |
1 review available for hydralazine and Inflammation
| Article | Year |
|---|---|
Pathophysiology and Current Clinical Management of Preeclampsia.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Delivery, Obstetric; Endothelium, | 2017 |
20 other studies available for hydralazine and Inflammation
| Article | Year |
|---|---|
Low-dose hydralazine reduces albuminuria and glomerulosclerosis in a mouse model of obesity-related chronic kidney disease.
Topics: Albuminuria; Animals; Diet, High-Fat; Disease Models, Animal; Fibrosis; Hydralazine; Inflammation; K | 2022 |
Xanthine oxidase/NADPH oxidase inhibition by hydralazine attenuates acute kidney injury and prevents the transition of acute kidney injury to chronic kidney disease.
Topics: Acute Kidney Injury; Animals; Enzyme Inhibitors; Fibrosis; Humans; Hydralazine; Inflammation; Kidney | 2023 |
Hydralazine Promotes Central Nervous System Recovery after Spinal Cord Injury by Suppressing Oxidative Stress and Inflammation through Macrophage Regulation.
Topics: Acrolein; Animals; Hydralazine; Inflammation; Macrophages; Mice; Neuralgia; Oxidative Stress; Phosph | 2023 |
The Therapeutic Value of Hydralazine in Reducing Inflammatory Response, Oxidative Stress, and Mortality in Animal Sepsis: Involvement of the PI3K/AKT Pathway.
Topics: Animals; Hydralazine; Inflammation; Oxidative Stress; Phosphatidylinositol 3-Kinases; Proto-Oncogene | 2021 |
Low-dose hydralazine during gestation reduces renal fibrosis in rodent offspring exposed to maternal high fat diet.
Topics: Albuminuria; Animals; Biomarkers; Body Weight; Collagen; Diet, High-Fat; DNA Methylation; Female; Fi | 2021 |
Acrolein involvement in sensory and behavioral hypersensitivity following spinal cord injury in the rat.
Topics: Acrolein; Animals; Behavior, Animal; Blotting, Western; Cold Temperature; DNA, Complementary; Electr | 2014 |
Excess salt causes cerebral neuronal apoptosis and inflammation in stroke-prone hypertensive rats through angiotensin II-induced NADPH oxidase activation.
Topics: Acetophenones; Angiotensin II; Animals; Antihypertensive Agents; Apoptosis; Astrocytes; Blood Pressu | 2008 |
Telmisartan prevents aneurysm progression in the rat by inhibiting proteolysis, apoptosis and inflammation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta, Abdominal; Aortic | 2008 |
HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Echocardiography; Histone Deacetylas | 2010 |
Angiotensin II infusion-induced inflammation, monocytic fibroblast precursor infiltration, and cardiac fibrosis are pressure dependent.
Topics: Angiotensin II; Animals; Blood Pressure; Fibrosis; Hydralazine; Hypertrophy, Left Ventricular; Infla | 2011 |
Late angiotensin II receptor blockade in progressive rat mesangioproliferative glomerulonephritis: new insights into mechanisms.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atenolol; Benzimidazoles; | 2013 |
Antioxidant activity and inhibitory effects of hydralazine on inducible NOS/COX-2 gene and protein expression in rat peritoneal macrophages.
Topics: Animals; Antioxidants; Cyclooxygenase 2; Dinoprostone; Free Radical Scavengers; Hydralazine; In Vitr | 2004 |
Heat shock treatment protects against angiotensin II-induced hypertension and inflammation in aorta.
Topics: Acrylates; Angiotensin II; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Blotting, Wester | 2004 |
Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage.
Topics: Albuminuria; Angiotensin II; Angiotensinogen; Animals; Animals, Genetically Modified; Antihypertensi | 2000 |
Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats.
Topics: Actins; Amides; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cardiovascular Diseases | 2002 |
Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis.
Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure; Capillaries; Chemokine CCL2; Endothelial | 2002 |
Morphological changes observed after stimulation or inhibition of adrenic system in rats chronically treated with hydrazinophtalazines.
Topics: Animals; Catecholamines; Epinephrine; Heart; Heart Diseases; Hemorrhage; Hydralazine; Inflammation; | 1979 |
Histopathological changes in experimental drug-induced collagen disease-like syndrome.
Topics: Animals; Blood Vessels; Collagen Diseases; Connective Tissue; Guinea Pigs; Hydralazine; Inflammation | 1977 |
Effects of thyroxine, oxyphenbutazone and imipramine on an inflammatory graft-versus-host reaction in chicks.
Topics: Animals; Atropine; Chickens; Gold; Graft vs Host Reaction; Hydralazine; Imipramine; Inflammation; Ly | 1972 |
Heterocyclic systems with a bridgehead nitrogen. II. 6-Chloroimidazo[2,1-b]thiazole and some of its 5-substituted derivatives.
Topics: Animals; Aspirin; Blood Pressure; Chemical Phenomena; Chemistry; Enterobacteriaceae; Female; Fungi; | 1969 |